$13.17
3.30% day before yesterday
Nasdaq, Dec 27, 09:50 pm CET
ISIN
US1266381052
Symbol
CVRX

CVRx Inc Stock price

$13.17
-2.14 13.98% 1M
+1.47 12.56% 6M
-18.27 58.11% YTD
-17.58 57.17% 1Y
+1.15 9.57% 3Y
-14.83 52.96% 5Y
-14.83 52.96% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.45 3.30%
ISIN
US1266381052
Symbol
CVRX
Sector

Key metrics

Market capitalization $319.55m
Enterprise Value $269.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.71
P/S ratio (TTM) P/S ratio 6.76
P/B ratio (TTM) P/B ratio 4.89
Revenue growth (TTM) Revenue growth 34.38%
Revenue (TTM) Revenue $47.26m
EBIT (operating result TTM) EBIT $-58.88m
Free Cash Flow (TTM) Free Cash Flow $-40.45m
Cash position $100.16m
EPS (TTM) EPS $-2.71
P/E forward negative
P/S forward 6.29
EV/Sales forward 5.31
Short interest 12.35%
Show more

Is CVRx Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

CVRx Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a CVRx Inc forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a CVRx Inc forecast:

Buy
71%
Hold
29%

Financial data from CVRx Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
47 47
34% 34%
100%
- Direct Costs 8.05 8.05
23% 23%
17%
39 39
37% 37%
83%
- Selling and Administrative Expenses 87 87
44% 44%
184%
- Research and Development Expense 11 11
15% 15%
22%
-58 -58
31% 31%
-123%
- Depreciation and Amortization 0.57 0.57
10% 10%
1%
EBIT (Operating Income) EBIT -59 -59
31% 31%
-125%
Net Profit -58 -58
37% 37%
-124%

In millions USD.

Don't miss a Thing! We will send you all news about CVRx Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CVRx Inc Stock News

Neutral
GlobeNewsWire
5 days ago
MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast.
Neutral
GlobeNewsWire
about one month ago
MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast.
Positive
Seeking Alpha
about 2 months ago
CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution.
More CVRx Inc News

Company Profile

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.

Head office United States
CEO Kevin Hykes
Employees 200
Founded 2001
Website www.cvrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today